Watson Pharmaceuticals, Inc.
WPI today confirmed that the U.S. Food and Drug Administration (FDA)
denied the Company's Formal Dispute Resolution Request (FDRR) related to its
pending New Drug Application (NDA) for Prochieve for the prevention of preterm
birth in women with a short cervical length. The Company said it intends to
review possible options related to the continued pursuit of the NDA. Watson
filed its FDRR in August of 2012.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in